NEW YORK – Fluidigm this week lost its patent suit against IonPath after the US District Court for the Northern District of California ruled that IonPath's MIBIscope technology does not infringe on its patents.
The court's judgment is appealable, however, and Fluidigm has indicated that it will likely appeal, telling GenomeWeb in a statement this month that it "intend[s] to continue to pursue all legal remedies available to us against IonPath."